{
    "clinical_study": {
        "@rank": "164880", 
        "arm_group": [
            {
                "arm_group_label": "Pylorex plus", 
                "arm_group_type": "Experimental", 
                "description": "Pylorex plus consisting of medicinal plants."
            }, 
            {
                "arm_group_label": "Quadruple therapy", 
                "arm_group_type": "Active Comparator", 
                "description": "Omeprazole, Amoxicillin, Metronodazole and TRITEC (ranitidine bismuth citrate)"
            }
        ], 
        "brief_summary": {
            "textblock": "Helicobacter pylori is strongly associated to the development of gastrointestinal disorders.\n      Emerging antibiotic resistance and poor patient compliance of modern therapies has resulted\n      in significant eradication failure. Clinical trial was conducted to see the efficacy of\n      current quadruple and phytomedicine-based therapies for the eradication of H. pylori\n      infection and relief in its associated symptoms in Pakistan."
        }, 
        "brief_title": "Quadruple and Phytomedicine-based Therapies in H. Pylori Infection", 
        "completion_date": {
            "#text": "January 2013", 
            "@type": "Actual"
        }, 
        "condition": "Helicobacter Pylori [H. Pylori] as the Cause of Diseases", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. The patients suffering from H. pylori infection\n\n          2. Patients having no previous record of treatment against H. pylori infection\n\n          3. Patients living in Karachi, Rawalpindi and Bahawalpur\n\n          4. Patients having no pathological complications on routine examination\n\n          5. All socioeconomic classes were included in the study\n\n          6. Male and female patients between 15 to 45 years of age\n\n        Exclusion Criteria:\n\n          1. there was peptic ulceration, gastrointestinal bleeding or gastric carcinoma\n\n          2. if history of use of antibiotics, proton-pump inhibitors or bismuth compound in the\n             last one month before test\n\n          3. any patient found to be allergic or intolerant to therapeutic regimens\n\n          4. they failed to report for follow-up"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "176", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 20, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02004197", 
            "org_study_id": "Asif-HP-001"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Pylorex plus", 
                    "Quadruple therapy"
                ], 
                "intervention_name": "Quadruple Allopathic therapy", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Omeprazol", 
                    "Amoxicillin", 
                    "Metronodazole", 
                    "TRITEC (ranitidine bismuth citrate)"
                ]
            }, 
            {
                "arm_group_label": [
                    "Pylorex plus", 
                    "Quadruple therapy"
                ], 
                "intervention_name": "Pylorex plus", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Amoxicillin", 
                "Bismuth tripotassium dicitrate", 
                "Ranitidine", 
                "Ranitidine bismuth citrate"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "December 5, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Karachi", 
                        "country": "Pakistan"
                    }, 
                    "name": "clinical trial was conducted in high risk areas of Pakistan such as Karachi, Bahawalpur, Islamabad and Rawalpindi at Shifa-Ul-Mulk Memorial Hospital, Hamdrad University Karachi, Bahawalpur Victoria Hospital and Nawaz Salik Hospital respectively"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Karachi", 
                        "country": "Pakistan"
                    }, 
                    "name": "Shifa Ul MUlk Memorial Hospital"
                }
            }
        ], 
        "location_countries": {
            "country": "Pakistan"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phytomedicine-based and Quadruple Therapies in Helicobacter Pylori Infection. A Comparative Randomized Trial", 
        "overall_official": {
            "affiliation": "Hamdard University Karachi", 
            "last_name": "Khan Usman Ghani, Ph. D", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Pakistan: Research Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "September 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "H. pylori eradication rate was the primary endpoint, which was considered to be achieved on the basis of a negative urea breath and stool antigen test four weeks after the end of treatment", 
            "safety_issue": "Yes", 
            "time_frame": "1 month"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02004197"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Shifa Ul Mulk Memorial Hospital", 
            "investigator_full_name": "Hafiz Muhammad Asif", 
            "investigator_title": "Doctor", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": {
            "measure": "The secondary endpoint was the improvement in the clinical features as assessed by an improvement in dyspepsia scores", 
            "safety_issue": "Yes", 
            "time_frame": "1 month"
        }, 
        "source": "Shifa Ul Mulk Memorial Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hafiz Muhammad Asif", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2010", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}